CDMO to expand global footprint with new German facility 

Vetter Pharma, a leading contract development and manufacturing organisation (CDMO) for injectable drugs, has confirmed plans to build a state-of-the-art production facility in Saarlouis, southwest Germany. Construction is scheduled to start in the second quarter of 2026, with operations expected to begin in 2031. The first phase of the project represents an investment of around €480 million.

The site, spanning approximately 95 acres, is expected to create up to 2,000 jobs over the long term. The European Commission has approved up to €47 million in state aid for the project, reflecting its strategic importance to the region. The new facility is part of Vetter’s broader €1.5 billion expansion plan in Europe and the US, reinforcing the company’s commitment to strengthening its global manufacturing network.

“Building a new production facility in Saarland allows us to combine stability with growth,” said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board. “This investment strengthens our ties to Germany’s economic landscape while supporting our role as a strategic partner to the global pharmaceutical market.”

In parallel, Vetter has begun constructing a new clinical production site in Des Plaines, Illinois, USA, focusing on aseptic manufacturing for early-stage clinical development. Together, these projects underline the company’s long-term strategy to expand capacity, enhance service quality, and meet growing global demand.

More information online